EVMN Company Profile and Key Details

Evommune, Inc. has 36.29 million shares outstanding. The public float is 19.88 million shares, elevated short interest at 18.28% of float. This equals 4.48 million shares. The short ratio is 5.44 days. Institutional investors hold 118.52% of the float. Insiders own 3.18%.

Short-term trend indicators are bearishly aligned (SMA20 7.47%, SMA50 28.22%, SMA200 30.82%). The stock’s 14-day RSI is 54.91 (neutral), while the ATR of 3.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.79% below its high and over 91.79% above its low. Average 10-day trading volume of 371.70 thousand shares is below the 3-month average of 773.94 thousand, indicating normal recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $65.00 to $26.00. The high target offers 429.75% upside. The low target suggests 111.9% downside. The mean target is $44.77. This offers 264.87% upside. Evommune, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by 33.94%. The prior quarter beat by -22.89%. Over the last six quarters, Apple has recorded several small beats. These include -5.02% in December 03, 2025.

Evommune, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$24.35. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Evommune, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.97%, with price expected at $11.66 by September 17, 2026, within a range of $10.79 to $12.52 3-Month Outlook: Projected fall of -6.11%, reaching $11.52 by December 02, 2026, with a range of $10.81 to $12.19. 1-Year Outlook: Projected loss of -40.1%, with price at $7.35 by September 03, 2027, within a range of $6.85 to $7.84.

Evommune, Inc. (NYSE:EVMN) closed at $12.27 USD, gaining $0.27 (2.25%) from the previous close of $12.00. The stock is currently mid-range between its 52-week high and low $10.47 and $33.20. With a market capitalization of about $445.30 million, Evommune, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.96). Key stats such as the average daily volume over the past year has been around 790.51 thousand shares, volume is running light vs its 52-week average. Headquartered in Palo Alto, CA, Evommune, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Luis C. Pena, the company employs approximately 48 people and listed since November 06, 2025. Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions.

Evommune, Inc. (NYSE:EVMN) shares are flat 7.48% year-to-date currently trading near 52-week highs band. Valuation shows Evommune, Inc. trading at a premium to the broader market with a P/E of -4.36. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $44.77, suggesting 264.87% upside. Our AI forecast model points to short-term weakness (-4.97% over two weeks), a medium-term fall (-6.11% over three months), and a longer-term loss (-40.1% over one year), with expected trading ranges indicating moderate volatility.

Evommune, Inc. trades at a P/E ratio of -4.36, slightly below the S&P 500 average, with a price-to-sales ratio of 44.78 and a price-to-book ratio of 1.61 suggesting the stock is closer to book value. The P/FCF stands at -6.0, also below market averages.